Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, Miyashita A, Okumura K, Nishiyama D, Hirakawa K, Shimura K, Kaneko H, Kiyota M, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Onishi A, et al. Among authors: kiyota m. Int J Hematol. 2024 Jan;119(1):50-61. doi: 10.1007/s12185-023-03680-1. Epub 2023 Dec 12. Int J Hematol. 2024. PMID: 38082201
Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.
Sasaki N, Shimura K, Yoshida M, Uoshima N, Kiyota M, Hatsuse M, Uchiyama H, Chinen Y, Kobayashi T, Nakao M, Takahashi R, Nakano-Akamatsu S, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) investigators. Sasaki N, et al. Among authors: kiyota m. Int J Hematol. 2019 Mar;109(3):278-285. doi: 10.1007/s12185-018-02583-w. Epub 2019 Jan 9. Int J Hematol. 2019. PMID: 30627868 Clinical Trial.
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: kiyota m. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, Tanaka T, Kamitsuji Y, Murakami S, Hatsuse M, Okano A, Iwai T, Ueda S, Koshida M, Uchiyama H, Matsumoto Y, Kaneko H, Uoshima N, Ueda Y, Kobayashi Y, Shimazaki C, Horiike S, Taniwaki M. Kobayashi T, et al. Among authors: kiyota m. Int J Hematol. 2010 Nov;92(4):579-86. doi: 10.1007/s12185-010-0696-4. Epub 2010 Oct 7. Int J Hematol. 2010. PMID: 20924731
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.
Tsukamoto T, Kiyota M, Kawata E, Uoshima N, Tatekawa S, Chinen Y, Nagoshi H, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Horiike S, Yasukawa S, Yanagisawa A, Taniwaki M, Kuroda J. Tsukamoto T, et al. Among authors: kiyota m. Int J Hematol. 2017 May;105(5):658-667. doi: 10.1007/s12185-016-2166-0. Epub 2016 Dec 19. Int J Hematol. 2017. PMID: 27995457
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida SI, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG). Matsumoto Y, et al. Among authors: kiyota m. Int J Hematol. 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. Epub 2019 May 24. Int J Hematol. 2019. PMID: 31127456 Clinical Trial.
100 results